1090 related articles for article (PubMed ID: 28544208)
1. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study.
Abrigo JM; Shen J; Wong VW; Yeung DK; Wong GL; Chim AM; Chan AW; Choi PC; Chan FK; Chan HL; Chu WC
J Hepatol; 2014 Apr; 60(4):809-15. PubMed ID: 24291241
[TBL] [Abstract][Full Text] [Related]
3. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
[TBL] [Abstract][Full Text] [Related]
4. Application of localized ³¹P MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease.
Valkovič L; Gajdošík M; Traussnigg S; Wolf P; Chmelík M; Kienbacher C; Bogner W; Krebs M; Trauner M; Trattnig S; Krššák M
Eur Radiol; 2014 Jul; 24(7):1602-9. PubMed ID: 24647824
[TBL] [Abstract][Full Text] [Related]
5. High resolution in vivo 31P-MRS of the liver: potential advantages in the assessment of non-alcoholic fatty liver disease.
Jeon MJ; Lee Y; Ahn S; Lee C; Kim OH; Oh BC; Yu U; Kim H
Acta Radiol; 2015 Sep; 56(9):1051-60. PubMed ID: 25270373
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling.
Sevastianova K; Hakkarainen A; Kotronen A; Cornér A; Arkkila P; Arola J; Westerbacka J; Bergholm R; Lundbom J; Lundbom N; Yki-Järvinen H
Radiology; 2010 Aug; 256(2):466-73. PubMed ID: 20656836
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
Firneisz G
World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
[TBL] [Abstract][Full Text] [Related]
8. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
[TBL] [Abstract][Full Text] [Related]
10. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
Bril F; Barb D; Lomonaco R; Lai J; Cusi K
J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
[TBL] [Abstract][Full Text] [Related]
11. Assessment of hepatic fatty acids during non-alcoholic steatohepatitis progression using magnetic resonance spectroscopy.
Xavier A; Zacconi F; Santana-Romo F; Eykyn TR; Lavin B; Phinikaridou A; Botnar R; Uribe S; Oyarzún JE; Cabrera D; Arrese M; Andia ME
Ann Hepatol; 2021; 25():100358. PubMed ID: 33962045
[TBL] [Abstract][Full Text] [Related]
12. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.
Masarone M; Troisi J; Aglitti A; Torre P; Colucci A; Dallio M; Federico A; Balsano C; Persico M
Metabolomics; 2021 Jan; 17(2):12. PubMed ID: 33458794
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous MR quantification of hepatic fat content, fatty acid composition, transverse relaxation time and magnetic susceptibility for the diagnosis of non-alcoholic steatohepatitis.
Leporq B; Lambert SA; Ronot M; Vilgrain V; Van Beers BE
NMR Biomed; 2017 Oct; 30(10):. PubMed ID: 28678410
[TBL] [Abstract][Full Text] [Related]
16. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
[TBL] [Abstract][Full Text] [Related]
17. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
18. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign.
Tobari M; Hashimoto E; Taniai M; Ikarashi Y; Kodama K; Kogiso T; Tokushige K; Takayoshi N; Hashimoto N
J Gastroenterol Hepatol; 2019 Aug; 34(8):1404-1410. PubMed ID: 30590868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
